Viridian’s Lumvoa approval breaks Tepezza’s TED monopoly. Inside the label, Phase 3 data, safety risks, payer hurdles and ...
Achieve’s cytisinicline CRL cited a prior facility and incomplete labeling, not clinical failure. Why this CMC rejection ...
FDA Issues CRL to Sobi for NASP in Uncontrolled Gout, but the letter did not attack the clinical case. It attacked ...
Unicycive OLC received a second FDA CRL over third-party manufacturing deficiencies. The case shows why CMC risk now drives ...
AlzeCure did not prove ACD856 works in Alzheimer’s patients. It proved something else: early clinical safety, brain exposure, and a novel CNS mechanism can still be valuable enough to move a small ...
The CMC Execution Crisis: Why Unicycive’s OLC CRL Is a Warning Shot for Every Indian CDMO | Witfire Elite View Witfire Elite CMC & Manufacturing Case Studies CDMO… ...
4SigHT is formally a long-term observational study. Strategically, its timing points to something larger: Tanabe is building a Japanese real-world evidence moat before Bristol Myers Squibb brings a ...
Phase 3 Data, Capital Structure and the Cost of Independence Revolution Medicines has not eliminated acquisition interest. It has eliminated the financial urgency that could force it to accept an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results